Literature DB >> 24366631

Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus.

Kunjal Patel1, Jiajia Wang, Denise L Jacobson, Steven E Lipshultz, David C Landy, Mitchell E Geffner, Linda A Dimeglio, George R Seage, Paige L Williams, Russell B Van Dyke, George K Siberry, William T Shearer, Luciana Young, Gwendolyn B Scott, James D Wilkinson, Stacy D Fisher, Thomas J Starc, Tracie L Miller.   

Abstract

BACKGROUND: Perinatally HIV-infected adolescents may be susceptible to aggregate atherosclerotic cardiovascular disease risk, as measured by the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) coronary arteries and abdominal aorta risk scores, as a result of prolonged exposure to HIV and antiretroviral therapy. METHODS AND
RESULTS: Coronary arteries and abdominal aorta PDAY scores were calculated for 165 perinatally HIV-infected adolescents, using a weighted combination of modifiable risk factors: dyslipidemia, cigarette smoking, hypertension, obesity, and hyperglycemia. Demographic and HIV-specific predictors of scores ≥1 were identified, and trends in scores over time were assessed. Forty-eight percent and 24% of the perinatally HIV-infected adolescents had coronary arteries and abdominal aorta scores ≥1, representing increased cardiovascular disease risk factor burden. Significant predictors of coronary arteries scores ≥1 included male sex, history of an AIDS-defining condition, longer duration of use of a ritonavir-boosted protease inhibitor, and no prior use of tenofovir. Significant predictors of abdominal aorta scores ≥1 included suppressed viral load, history of an AIDS-defining condition, and longer duration of boosted protease inhibitor use. No significant changes in coronary arteries and abdominal aorta risk scores were observed over the 4-year study period.
CONCLUSIONS: A substantial proportion of perinatally HIV-infected youth have high PDAY scores, reflecting increased aggregate atherosclerotic cardiovascular disease risk factor burden. High scores were predicted by HIV disease severity and boosted protease inhibitor use. PDAY scores may be useful in identifying high-risk youth who may benefit from early lifestyle or clinical interventions.

Entities:  

Keywords:  HIV; adolescence; atherosclerosis; risk factors

Mesh:

Year:  2013        PMID: 24366631      PMCID: PMC3991841          DOI: 10.1161/CIRCULATIONAHA.113.001978

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  40 in total

1.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

2.  Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine.

Authors:  S M Arpadi; P A Cuff; M Horlick; J Wang; D P Kotler
Journal:  J Acquir Immune Defic Syndr       Date:  2001-05-01       Impact factor: 3.731

3.  High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection.

Authors:  Jason Baker; Woubeshet Ayenew; Harrison Quick; Katherine Huppler Hullsiek; Russell Tracy; Keith Henry; Daniel Duprez; James D Neaton
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

4.  Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.

Authors:  Grace M Aldrovandi; Jane C Lindsey; Denise L Jacobson; Amanda Zadzilka; Elizabeth Sheeran; Jack Moye; Peggy Borum; William A Meyer; Dana S Hardin; Kathleen Mulligan
Journal:  AIDS       Date:  2009-03-27       Impact factor: 4.177

5.  Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation.

Authors:  S Parra; B Coll; G Aragonés; J Marsillach; R Beltrán; A Rull; J Joven; C Alonso-Villaverde; J Camps
Journal:  HIV Med       Date:  2009-10-21       Impact factor: 3.180

6.  Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1.

Authors:  Tracie L Miller; E John Orav; Steven E Lipshultz; Kristopher L Arheart; Christopher Duggan; Geoffrey A Weinberg; Lori Bechard; Lauren Furuta; Jeanne Nicchitta; Sherwood L Gorbach; Abby Shevitz
Journal:  J Pediatr       Date:  2008-06-09       Impact factor: 4.406

Review 7.  Effects of HIV protease inhibitor therapy on lipid metabolism.

Authors:  David Y Hui
Journal:  Prog Lipid Res       Date:  2003-03       Impact factor: 16.195

8.  Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study.

Authors:  Shengxu Li; Wei Chen; Sathanur R Srinivasan; M Gene Bond; Rong Tang; Elaine M Urbina; Gerald S Berenson
Journal:  JAMA       Date:  2003-11-05       Impact factor: 56.272

9.  Impact of HIV infection and HAART on serum lipids in men.

Authors:  Sharon A Riddler; Ellen Smit; Stephen R Cole; Rui Li; Joan S Chmiel; Adrian Dobs; Frank Palella; Barbara Visscher; Rhobert Evans; Lawrence A Kingsley
Journal:  JAMA       Date:  2003-06-11       Impact factor: 56.272

10.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Authors:  Signe Westring Worm; Caroline Sabin; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Eric Fontas; Ian Weller; Andrew Phillips; Jens Lundgren
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

View more
  26 in total

Review 1.  Perinatally infected adolescents living with human immunodeficiency virus (perinatally human immunodeficiency virus).

Authors:  Maria Leticia S Cruz; Claudete A Cardoso
Journal:  World J Virol       Date:  2015-08-12

Review 2.  Of mice and monkeys: can animal models be utilized to study neurological consequences of pediatric HIV-1 infection?

Authors:  Heather Carryl; Melanie Swang; Jerome Lawrence; Kimberly Curtis; Herman Kamboj; Koen K A Van Rompay; Kristina De Paris; Mark W Burke
Journal:  ACS Chem Neurosci       Date:  2015-06-19       Impact factor: 4.418

3.  HIV-infected Children in Malawi Have Decreased Performance on the 6-minute Walk Test With Preserved Cardiac Mechanics Regardless of Antiretroviral Treatment Status.

Authors:  Amy E Sims Sanyahumbi; Mina C Hosseinipour; Danielle Guffey; Irving Hoffman; Peter N Kazembe; Madeline McCrary; Charles G Minard; Charles van der Horst; Craig A Sable
Journal:  Pediatr Infect Dis J       Date:  2017-07       Impact factor: 2.129

4.  Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.

Authors:  Ann J Melvin; Grace Montepiedra; Lisa Aaron; William A Meyer; Hans M Spiegel; William Borkowsky; Mark J Abzug; Brookie M Best; Marilyn J Crain; Peggy R Borum; Bobbie Graham; Patricia Anthony; Katherine Shin; George K Siberry
Journal:  Pediatr Infect Dis J       Date:  2017-01       Impact factor: 2.129

5.  Acceptability of Family-Centered Advanced Care Planning for Adolescents With HIV.

Authors:  Ronald H Dallas; Allison Kimmel; Megan L Wilkins; Sohail Rana; Ana Garcia; Yao I Cheng; Jichuan Wang; Maureen E Lyon
Journal:  Pediatrics       Date:  2016-11-01       Impact factor: 7.124

6.  Insulin Resistance in South African Youth Living with Perinatally Acquired HIV Receiving Antiretroviral Therapy.

Authors:  Lisa J Frigati; Jennifer Jao; Sana Mahtab; Nana-Akua Asafu Agyei; Mark F Cotton; Landon Myer; Heather J Zar
Journal:  AIDS Res Hum Retroviruses       Date:  2018-09-25       Impact factor: 2.205

7.  Paediatric advance care planning survey: a cross-sectional examination of congruence and discordance between adolescents with HIV/AIDS and their families.

Authors:  Maureen E Lyon; Ronald H Dallas; Patricia A Garvie; Megan L Wilkins; Ana Garcia; Yao Iris Cheng; Jichuan Wang
Journal:  BMJ Support Palliat Care       Date:  2017-09-21       Impact factor: 3.568

8.  Brain arterial remodeling contribution to nonembolic brain infarcts in patients with HIV.

Authors:  Jose Gutierrez; James Goldman; Andrew J Dwork; Mitchell S V Elkind; Randolph S Marshall; Susan Morgello
Journal:  Neurology       Date:  2015-08-28       Impact factor: 9.910

9.  Declining Incidence of Systolic Left Ventricular Dysfunction in Human Immunodeficiency Virus-Infected Individuals Treated With Highly Active Antiretroviral Therapy.

Authors:  Stacy D Fisher; Thomas J Starc; Vitor Guerra; Paige L Williams; James D Wilkinson; Steven E Lipshultz
Journal:  Am J Cardiol       Date:  2016-01-14       Impact factor: 2.778

10.  Cardiac Effects of Highly Active Antiretroviral Therapy in Perinatally HIV-Infected Children: The CHAART-2 Study.

Authors:  Steven E Lipshultz; James D Wilkinson; Bruce Thompson; Irene Cheng; David A Briston; William T Shearer; E John Orav; Joslyn A Westphal; Tracie L Miller; Steven D Colan
Journal:  J Am Coll Cardiol       Date:  2017-10-31       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.